KH-CB19

• Description :

  KH-CB19 is a potent CLK (cdc2-like kinase) inhibitor (CLK1 IC50=19.7 nM; CLK3 IC50=530 nM) . KH-CB19 shows antiviral activity and inhibits influenza virus replication (IC50=13.6 μM) [1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Infection; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/KH-CB19.html

• Purity :

  99.31

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  CCOC(C1=C(C2=C(C(Cl)=C(C=C2)Cl)N1C)/C(C#N)=C\N)=O

• Molecular Formula :

  C15H13Cl2N3O2

• Molecular Weight :

  338.19

• Precautions :

  H302

• References & Citations :

  [1]Fedorov O, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18 (1) :67-76.|[2]Artarini A, et al. Regulation of influenza A virus mRNA splicing by CLK1. Antiviral Res. 2019 Aug;168:187-196.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CLK

• CAS Number :

  [1354037-26-5]